These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29164151)

  • 1. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
    Li Z; Liu Y; Zhang Y; Shao X; Luo Q; Guo X; Lin G; Cai Q; Zhao Z; Chong Y
    Biomed Res Int; 2017; 2017():9849823. PubMed ID: 29164151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.
    Li Z; Zhang Y; Liu Y; Shao X; Luo Q; Cai Q; Zhao Z
    Medicine (Baltimore); 2017 May; 96(19):e6830. PubMed ID: 28489763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of drug resistance mutations on antiviral agents in HCV patients.
    Liu G; Cai Q; Li Z; Shao X; Luo Q; Zhang X; Zhao Z
    Antivir Ther; 2016; 21(5):369-75. PubMed ID: 25222865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
    Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
    PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
    Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
    Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China].
    Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
    PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.
    Patiño-Galindo JÁ; Salvatierra K; González-Candelas F; López-Labrador FX
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2402-16. PubMed ID: 26856832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
    Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
    Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
    PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
    Wang Y; Rao HY; Xie XW; Wei L
    Chin Med J (Engl); 2015 Oct; 128(19):2625-31. PubMed ID: 26415801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa.
    Maunye TK; Gededzha MP; Blackard JT; Rakgole JN; Selabe SG
    Intervirology; 2023; 66(1):77-87. PubMed ID: 37231989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
    Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
    Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.